May 16 |
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCEĀ®)
|
May 11 |
Arvinas, Inc. (NASDAQ:ARVN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
|
May 9 |
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
|
May 8 |
We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth
|
May 7 |
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
|
May 7 |
Arvinas GAAP EPS of -$0.97 beats by $0.37, revenue of $25.3M misses by $6.76M
|
May 7 |
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
May 2 |
Why Earnings Season Could Be Great for Arvinas (ARVN)
|
May 2 |
Arvinas to Present at Upcoming Investor Conferences
|
May 1 |
Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?
|